Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Effect of Interleukin-1β Inhibition With Canakinumab on Incident Lung Cancer in Patients With Atherosclerosis: Exploratory Results From a Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 2017 Aug 25;[EPub Ahead of Print], PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ GlynnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.